

ORIGINAL

sfw

Attorney Docket No. LeA 36 230

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hendrix, et al.

Group No.:

Serial No.: 10/525,115

Examiner:


Filed: 18 February 2005

For: Phenyl-Substituted Pyrazolopyrimidines

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 11 April 2006


Gil Cunha

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.


IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed within three months of the filing or nationalization of this application, or before the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.


Respectfully submitted,


Susan M. Pellegrino
Attorney for Applicant(s)
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516

Reg. No.: 48,972

Telephone: (203) 812-6450

Date: 11 April 2006



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet	1	of	4
-------	---	----	---

Complete if Known

Application Number	10/525,115
Filing Date	18 February 2005
First Named Inventor	Hendrix, et al.
Art Unit	
Examiner Name	
Attorney Docket Number	LeA 36 230

[illegible]

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			
	F1	CH 396,924	08-15-1965	CIBA AG	
	F2	CH 396,925	08-15-1965	CIBA AG	
	F3	CH 396,926	08-15-1965	CIBA AG	
	F4	CH 396,927	08-15-1965	CIBA AG	
	F5	DE 2,408,906	02-25-1974	Chemische Fabrik von Heyden GmbH	

Examiner
Signature

Date	
Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/525,115		
		Filing Date	18 February 2005		
		First Named Inventor	Hendrix, et al.		
		Art Unit			
Examiner Name					
Sheet	2	of	4	Attorney Docket Number	LeA 36 230

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	WEI, et al., Molecular and Pharmacological Analysis of Cyclic Nucleotide-Gated Channel Function in the Central Nervous System, Progress in Neurobiology, vol. 56, 1998, pp. 37-64	
	R2	FISHER, et al., Isolation and Characterization of PDE9A, A Novel Human cGMP-specific Phosphodiesterase, Journal of Biological Chemistry, vol. 273, no. 25, 1998, pp. 15559-15564	
	R3	GUIPPONI, et al., Identification and Characterization of a Novel Cyclic Nucleotide Phosphodiesterase Gene (PDE9A) That Maps to 21q22.3: Alternative Splicing of mRNA Transcripts, Genomic Structure and Sequence, Hum Genet, vol. 103, 1998, pp. 386-392	
	R4	SONDERLING, et al., Identification and Characterization of a Novel Family of Cyclic Nucleotide Phosphodiesterases, Journal of Biological Chemistry, vol. 273, no. 25, pp. 15553-15558	
	R5	ANDREEVA, et al., Expression of cGMP-Specific Phosphodiesterase 9A mRNA in the Rat Brain, Journal of Neuroscience, vol. 21, no. 22, 2001, pp. 9068-9076	
	R6	MARTINS, et al., Purification and Characterization of a Cyclic GMP-stimulated Cyclic Nucleotide Phosphodiesterase from Bovine Tissues, Journal of Biological Chemistry, vol. 257, no. 4, 1982, pp. 1973-1979	
	R7	FRANCIS, et al. Characterization of a Novel cGMP Binding Protein from Rat Lung, Journal of Biological Chemistry, vol. 255, no. 2, 1980, pp. 620-626	
	R8	GILLESPIE, et al., Characterization of a Bovine Cone Photoreceptor Phosphodiesterase Purified by Cyclic GMP-Sepharose Chromatography, Journal of Biological Chemistry, vol. 263, no. 17, 1988, pp. 8133-8141	
	R9	FAWCETT, et al., Molecular Cloning and Characterization of a Distinct Human Phosphodiesterase Gene Family: PDE11A, Proc. Natl. Acad. Sci., vol. 97, no. 7, 2000, pp. 3702-3707	
	R10	MURASHIMA, et al., Characterization of Particulate Cyclic Nucleotide Phosphodiesterases from Bovine Brain: Purification of a Distinct cGMP-Stimulated Isoenzyme, Biochemistry, vol. 29, no. 22, 1990, pp. 5285-5292	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/525,115
		Filing Date	18 February 2005
		First Named Inventor	Hendrix, et al.
		Art Unit	
		Examiner Name	
Sheet 3	of 4	Attorney Docket Number	LeA 36 230

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R11	SODERLING, et al., Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions, Current Opinion in Cell Biology, vol. 12, 2000, pp. 174-179	
	R12	MIYASHITA, et al., Studies on Pyrazolo[3,4-d]Pyrimidine Derivatives. XVIII. Facile Preparation of 1H-Pyrazolo[3,4-d]Pyrimidin-4(5H)-Ones, Heterocycles, vol. 31, no. 7, 1990, p 1309-1314	
	R13	SCHMIDT, et al., Heilmittelchemische Studien in der Heterocyclischen Reihe 34. Mitteilung ¹⁾ Pyrazolo-pyrimidine V ²⁾ Eine neue Synthese von Pyrazolo[3,4-d]Pyrimidinen mit coronarerweiternden Eigenschaften, Helvetica Chimica Acta, no. 189, 1962, pp. 1620-1627	
	R14	LOUGHNEY, et al., Isolation and Characterization of cDNAs Corresponding to Two Human Calcium, Calmodulin-regulated, 3',5'-Cyclic Nucleotide Phosphodiesterases, Journal of Biological Chemistry, vol. 271, no. 2, 1996, pp. 796-806	
	R15	ROSMAN, et al., Isolation and Characterization of Human cDNAs encoding a cGMP-stimulated 3',5'-Cyclic Nucleotide Phosphodiesterase, Gene, vol. 191, 1997, pp. 89-95	
	R16	MIKI, et al., Characterization of the cDNA and Gene Encoding Human PDE3B, the cGIP1 Isoform of the Human Cyclic GMP-Inhibited Cyclic Nucleotide Phosphodiesterase Family, Genomics, vol. 36, 1996, pp. 476-485	
	R17	OBERNOLTE, et al., The cDNA of a Human Lymphocyte cyclic-AMP Phosphodiesterase (PDE IV) Reveals a Multigene Family, Gene, vol. 129, 1993 pp. 239-247	
	R18	LOUGHNEY, et al., Isolation and Characterization of cDNAs encoding PDE5A, a Human cGMP-Binding, cGMP-Specific 3',5'-Cyclic Nucleotide Phosphodiesterase, Gene, vol. 216, 1998, pp. 139-147	
	R19	HETMAN, et al., Cloning and Characterization of PDE7B, a cAMP-specific Phosphodiesterase, Proc. Natl. Acad. Sci., vol. 97, no. 1, 2000, pp. 472-476	
	R20	FISHER, et al., Isolation and Characterization of PDE8A, a Novel Human cAMP-Specific Phosphodiesterase, Biochemical and Biophysical Research Communications, vol. 246, 1998, pp. 570-577	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/525,115
				Filing Date	18 February 2005
				First Named Inventor	Hendrix, et al.
				Art Unit	
				Examiner Name	
Sheet	4	of	4	Attorney Docket Number	LeA 36 230

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.